ERIKA TOKUYAMA: Open Payments
NPI 1508450453 · LOVELAND, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,056 in 112 payments from 18 companies in 2025. Trend: 2023 $1,435 · 2024 $1,877 · 2025 $6,056
Consulting: $3,550Food & beverage: $2,263Education: $145Travel & lodging: $98
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 10 | $2,942 |
| Incyte Corporation | 3 | $1,080 |
| Galderma Laboratories, L.P. | 18 | $399 |
| ABBVIE INC. | 20 | $325 |
| Novartis Pharmaceuticals Corporation | 12 | $309 |
| Organon LLC | 9 | $142 |
| PFIZER INC. | 10 | $137 |
| Janssen Biotech, Inc. | 5 | $133 |
| UCB, Inc. | 5 | $118 |
| GENZYME CORPORATION | 4 | $112 |
Products named: EBGLYSS, NEMLUVIO, SKYRIZI, DUPIXENT, TREMFYA, COSENTYX, Bimzelx, CIBINQO.
Industry payments across CO — which companies pay providers there.
